icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Substantial
Substantial in the treatment of SJIA.
Clinical Added Value
moderate
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.
eNq1mFFv2jAQx9/5FFHeSUhLoZ0C1cbaDalVGS3atJfKJEcxS+30bAPdp59DqAaTow4HP8Z2/nfx/f3zKfHl+jnzloCCctbzo6Dle8ASnlL21PMnD9fNc/+y34gXZEl2lnWDVhCd+F6SESF6fjEbTIEwEfy4vfkM+n1Av9/wYj5dQCL31ilJs+ArEfNbkhdrvHjJaeo9g5zztOfnSm5GvVhI1Fn0Vxx/iZwkEIfbkd3ZxWN7dzwOC7H/UFUC8IawJ6MoMCvNRCECkwMi4Ynja0W+p1baVIxBcIUJjIicj5AvaQqpMcSMZAKsgsxW6T3gMgNZBDGKh4vkWViJkwVZj+FlaE76o54dyLVstppRt33R6nTbp1Gn07UKhTtbZa6C/ogweYy6p2edk7ZlQUYcJckclYKKwb6bHMVBeHm35CkVeUZeg4XIbbeKINHTgPrMu/uQ4gseUFMo03v2jz5TWRYemPVkywhHGRcIGnDFZAUqrse2GzHgTMK6uqJ2dJPrrRcpiOPJ/ubMTPaRmmY0seWYJo0CISfjYTXGahPgExEwQXcI+E5Zylfi+GjZLaWj7PMNHY2iOabR48nFeSc6O7M+OT+1byrukiuFPIdQQ4eKOiwZshmvSxFtRbPUmxHreXDTxvCEZFDRyDQtKaLN99Z3ObO3u6NTThhFv1w92HrimwJ8vd88GqVp2qtXzcQFt7UDKxM/3M/lsXbS4io042IuZS4+hOFqtQrmRDQF0bsUzPA4DN+5K9111U4u5LJBKTnoKPVpecEdVhbb4/XelV23Dd2+v213jTEkKqhRi5LEzng5vDo+gv/2oM7SHu0hw12YTb9IJOXMVUujpkbFuggasmvUgLibzWjFX45KX8Zh+Yel34jD4u9Kv/EHvkbUNw==
pENF6CyTNCKTCUUg